Tumor ablation due to inhomogeneous -- anisotropic diffusion in generic
  3-dimensional topologies by Kara, Erdi et al.
Tumor ablation due to inhomogeneous – anisotropic
diffusion in generic 3-dimensional topologies
Erdi Kara†, Aminur Rahman∗†, Eugenio Aulisa†, Souparno Ghosh ‡
Abstract
We derive a full 3-dimensional (3-D) model of inhomogeneous – anisotropic diffusion
in a tumor region coupled to a binary population model. The diffusion tensors are
acquired using Diffusion Tensor Magnetic Resonance Imaging (DTI) from a patient
diagnosed with glioblastoma multiform (GBM). Then we numerically simulate the
full model with Finite Element Method (FEM) and produce drug concentration heat
maps, apoptosis regions, and dose-response curves. Finally, predictions are made about
optimal injection locations and volumes, which are presented in a form that can be
employed by doctors and oncologists.
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1 Introduction
Among the various types of tumors, brain tumors are associated with very high mortality.
The five-year survival rate for people with a malignant brain or central nervous system tumor
is approximately 34% for men and 36% for women in the United States and brain tumors
account for 85% to 90% of all primary central nervous system tumors [1].
One of the major obstacles to improve current treatments is the presence of some physical
barriers such as the blood-brain barrier and the bloodbrain tumor barrier impeding drugs
from reaching the tumor sites in the brain [2, 3, 4]. The blood-brain barrier (BBB), existing
between the brains microvessels and tissue, prevents many macromolecules from entering
interstitial space in the brain; thus separating the central nervous system and systemic
circulation of the body. It is reported in [5] that BBB prevents entry of approximately 98%
of the small molecules and nearly 100% of large molecules, such as recombinant proteins or
gene-based medicines into brain tumors from the vascular compartment. Similarly, the blood-
brain tumor barrier (BBTB) is located between brain tumor tissues and the brain’s blood
vessels formed by highly specialized endothelial cells, limiting the delivery of most anti-cancer
drugs to tumor tissue. To overcome the challenges associated with these barriers, several
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methods have been developed such as intrarterial administration, barrier disruption, drug
packaging, and inhibiting drug efflux from tumors [6]. Regardless, oral and intravascular
administration allows only a small fraction of therapeutic agents to reach the tumor region
in the brain because the drug concentration decreases precipitously due to the sink effect
of the extracellular space along the route of drug transport to the tumor region. Thus,
necessitating the administration of a high dose to achieve sufficient drug concentrations to
kill the tumor cells. Unfortunately, physiological toxicity limits the amount of therapeutic
agent allowed in a particular therapy.
Significant effort has gone into developing therapies with high efficacy to toxicity ratios
through the use of lower drug concentrations via direct administration in targeted regions.
One such method is discussed in de Boer et al. [5]. Drug injection therapies allow for
uncomplicated individualized treatment for solid accessible tumors [5, 7, 8, 9, 10]. Further,
these types of therapies provide us with an opportunity to optimize drug efficacy by changing
the fluidic properties of the injection as shown by Morhard et al. [9]. While testing a variety
of therapeutic agents on animals is time intensive and costly, numerical simulations may
prove to be a cheap and effective solution.
In order to conduct numerical experiments on the effects of drugs on cancerous tumors,
we need transport – population coupled models. This may seem counter-intuitive to the
goal of developing fast methods to determine efficacy and toxicity due to how computation-
ally intensive sophisticated coupled models can be. Recent review articles and books show
evidence of this in the wealth of transport models [11, 12], and separately in the variety
of population models [13]; yet there is a dearth of coupled transport – population models.
Further, while there are many sophisticated transport models for drugs penetrating into the
tumor from the blood stream (e.g. [14, 15, 16]), there are few mathematical investigations
of drugs injected into the tumor.
In [17], Rahman et al. present a simple drug diffusion – binary population model. It is
assumed that a drug is being injected directly into the center of a homogeneous – isotropic
spherical tumor, and hence the diffusion is radial with constant diffusivity. Furthermore, it is
assumed that a cell is either dead if the concentration of the drug is greater than a threshold
and alive if the concentration is less than this threshold; i.e., the drug acts as a trigger for cell
death. From this model dose-response curves (response as a function of dose) are produced
in order to relate it to relevant empirical data, such as Harvard Medical School’s LINCS
data set. Since the data set does not include replication studies, artificial replication dose-
response curves were produced, and the dose-response curves from the mechanistic model
were shown, in many cases, to lie within 95% piecewise-linear confidence bands.
While the model of Rahman et al. [17] performed well against artificial replication data,
the simplicity is burdened by the baggage of assumptions. Transport of drugs in the brain is
a complex process due to the highly inhomogeneous and anisotropic structure of brain tissue,
local pressure differences, and chemcial interactions of the drug with the surrounding tissue.
However, a model that does not obviate negligible contributions falls prey to computational
constraints. Even with parallelization on a supercomputing cluster, would it be useful to an
oncologist that is working directly with a patient?
In this investigation, we keep the simple binary population model, and explore the com-
plexities of drug transport from a single injection into deformed globular tumors (topological
3-spheres). It is well known that diffusion dominates, but we assume it can be inhomogeneous
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and anisotropic. This allows for fast in vivo simulations of direct injection therapies, which
we use to produce dose-response curves, apoptosis regions, and optimal injection locations.
This investigation endeavors to present results to aid practitioners in optimizing treatment
strategies.
The remainder of the paper is organized as follows: We begin our discussions by deriving
the inhomogeneous - anisotropic diffusion and binary population models in Sec. 2. Then in
Sec. 3, we develop the computational foundation of the investigation in two steps. First, Sec.
3.1 sets up the finite element scheme. We use Galerkin Finite Element Method for the spatial
discretization and a Crank-Nicolson scheme for the temporal integration. Then the diffusion
tensors are constructed from patient MRI data in Sec. 3.2. Section 4 presents the numerical
simulations and oncological predictions of our study. We first examine the drug diffusion
in the tumor and observe the high inhomogeneity and anisotropy in the concentration heat
maps. Then the apoptosis is simulated by invoking the binary population model. This allows
us to create dose-response curves. Importantly, the model predicts optimal injection sites,
evidenced by the dose-response curves, different from what intuition might suggest. Finally,
the investigation is concluded in Sec. 5 with a discussion on viable oncological applications
and future modeling directions.
2 Drug diffusion and binary population models
In this section we derive the inhomogenous – anisotropic diffusion model and the binary
tumor population model. First we write a general diffusion model. It has been shown
through Magnetic Resonance Imaging (MRI) in the brain that tumors often grow in an
inhomogeneous – anisotropic diffusion-like manner [18, 19, 20, 21]. Using Diffusion Tensor
Imaging (DTI) techniques [22], the effective diffusivity of water in tissue can be estimated.
Since there is a large contrast between cancerous and healthy tissues, DTI can be used to
map the geometry of a tumor and estimate the diffusivity of water in a tumor [23, 24, 25].
Consider a drug with molarity u diffusing from an injection into a porous tumor, with an
effective diffusivity tensor D. Next for the sake of brevity, let x = (x1, x2, x3) be the position
vector. Finally, we model the leak at the boundary of the region of interest as “Newton’s
law of cooling” [26]. This gives us the generic model in Cartesian coordinates
∂u(x; t)
∂t
= ∇ · (D(x)∇u(x; t)) , x ∈ Ω; (1a)
D(x)∇u(x; t) · n = −γu(x; t), x ∈ ∂Ω; (1b)
u(x; t = 0) = u¯(x), (1c)
where u¯(x) is some generic initial concentration profile of the drug soon after injection and
γ is the constant leak coefficient. Since all the cells at the boundary are assumed to be
non-cancerous, the rate of leakage is equivalent to the rate of diffusion at the boundary.
We now impose a specific initial condition. In [17] a bump function (compact Gaussian)
decaying to zero just within the domain was used. During inhomogeneous – anisotropic
diffusion, the drug does not diffuse evenly, and hence a bump function that extends to the
endpoints would not capture the irregularities expected in such a problem. Nevertheless,
there are many numerical advantageous to using a bump function. We may either introduce
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a sharper bump or try to capture the diffusive irregularities in the initial condition. In
general, for an injection at point xc, we have
u¯(r) =
U0
Vb
exp
(
1− R
2
b
R2b − r2
)
, r < Rb
0, r ≥ Rb
(2)
where, r = ‖x− xc‖, Rb is the radius of the bump, U0 is the injected concentration, and Vb
is the volume of the bump function in spherical coordinates; that is,
Vb =
∫ pi
0
∫ 2pi
0
∫ Rb
0
exp
(
1− R
2
b
R2b − r2
)
r2 sinφdrdθdφ
2.1 Binary population model
As done in [17], we use a binary population model: the tumor cell is dead after some exposure
time τ (which is much larger than the diffusive time scale), if at any time during the diffusion
process the drug concentration is above some given threshold value uT (τ), otherwise it is
alive. To simplify computation, the model assumes natural cell death rate is equivalent to
the cell population growth rate, and effectively negate each other. We expect the threshold
to decrease with time because it takes more toxins to kill a cell quickly than it does to kill it
slowly. Further, since empirical studies often plot response data against log time, we expect
uT to be a negative exponential with time τ ,
uT (τ) = a− be−cτ , (3)
where the parameters a, b, and c are back calculated from a representative sample of the
Harvard Medical School LINCS drug data set. From the representative sample we calculate
what uT (τ = 24 hrs), uT (τ = 48 hrs), uT (τ = 72 hrs) must be in order to produce the
empirically observed response. Then we have three equations with three unknowns, which
is solved explicitly in [17]. In this paper, we use the following threshold values.
uT (24) = 0.230153 µM, uT (48) = 0.0700055 µM, uT (72) = 0.0499662 µM
3 Numerical procedure
In this section, we first describe the numerical procedure to approximate the solution of
the system (1) in Sec. 2. Galerkin finite element method (GFEM) is used for the spatial
discretization and a Crank-Nicolson scheme for the temporal integration. For a practical
introduction finite element method, reader can refer to [27].
For the inhomogeneous – anisotropic diffusivity we incorporate diffusion tensors from
diffusion tensor magnetic resonance imaging (DTI) data. The magnetic field gradients in
different directions from the MRI is used to map out directions of faster and slower diffusion
that is normalized to the diffusivity of water molecules. While in medical imaging the
diffusion tensor is predominantly used to identify anomalies, and often averaged out in
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preferential directions for that reason, we use it in the diffusivity of the transport model.
Since the only errors are from the DTI data and GFEM, we can produce accurate qualitative
simulations of in vivo scenarios.
There are a few studies in the literature integrating FEM with DT-imaging in a mod-
eling framework. Kraft et al. incorporated DTI with FEM to investigate the mechanics of
neurotrauma [28]. In [29], Ramasamy et al. proposed a subject-specific finite element model
for the residual limb to assess the effect of a particular socket on deep tissue injury. They
utilized DTI to reveal the anatomy of muscle fiber and mapped the information onto a finite
element mesh. A nonlinear hyperelastic, transversely isotropic skeletal muscle constitutive
law containing a deep tissue injury model were then solved with FEM. Clatz et al. [30]
used FEM to simulate the invasion of GBM in the brain parenchyma and its mass effect on
the invaded tissue. They described a coupling strategy between reaction-diffusion and linear
elastic mechanical constitutive equations where diffusion tensor information was provided
by DTI. In [31], a convection-enhanced drug delivery (CED), where the anti-cancer agent is
directly administered into the brain tissue, was introduced. Governing equations concerning
the transport of the therapeutic agent and tissue deformation was solved with the Finite Vol-
ume Method, where the information about the structures of the tissue is acquired through
DTI.
3.1 Finite element discretization
Consider the Sobolev space H1(Ω) = {v ∈ L2(Ω) : ∂xiv ∈ L2(Ω) i = 1, 2, 3}, where Ω is the
domain of the PDE from Sec. 2. If u is sufficiently smooth, by multiplying (1a) with a test
function v ∈ H1(Ω) and integrating over Ω using Green’s formula, we obtain the variational
formulation of (1a); that is, find u such that for every t ∈ I = [0, T ],∫
Ω
∂u
∂t
vdx = −
∫
Ω
D∇u · ∇vdx−
∫
∂Ω
γuvds, ∀v ∈ H1(Ω), t ∈ I. (4)
Let
Ωh = {K1, K2, .., Kn} (5)
be a geometrically conforming hexagonal triangulation of Ω. As a test space, we use the
space of scalar valued piece-wise quadratic polynomials; i.e.,
Vh = {p ∈ C0(Ω¯) : p|K ∈ Q2(K), ∀K ∈ Ωh} ⊂ H1(Ω).
Replacing H1(Ω) with Vh, the finite element formulation of (4) reads: find uh such that for
every t ∈ I,∫
Ω
∂uh
∂t
vhdx = −
∫
Ω
D∇uh · ∇vhdx−
∫
∂Ω
γuhvhds, ∀vh ∈ Vh, t ∈ I. (6)
Let {ψi}ni=1 be a basis of the space Vh consisting of the orthogonal nodal basis functions
satisfying ψi(Nj) = δij for every nodal point Nj. For every uh ∈ Vh, there exist time
dependent coefficients ξj(t) such that
uh(x, t) =
n∑
j=1
ξj(t)ψj(x). (7)
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From this construction, ξj(t)’s are the nodal values of uh for every time t. If we substitute
(7) in (6), we obtain the following system of ordinary differential equations (ODEs)
M ˙ξ(t) = −(A+R)ξ(t), (8)
where ξ(t) = [ξ1(t), ξ2(t), .., ξn(t)]
T and
Mij =
∫
Ω
ψjψi, Aij =
∫
Ω
D∇ψj · ∇ψi, Rij =
∫
∂Ω
γψjψi. (9)
Note that the diffusion tensor D is defined element-wise. Let 0 = t0 < t1 < . . . < tN = T
be a partition of the interval [0, T ] with the constant time step ∆t = tn+1 − tn. Application
of the Crank-Nicolson scheme for (8) yields
M
ξk+1 − ξk
∆t
= −(A+R)ξk + ξk+1
2
, (10)
where ξ0 is chosen as the nodal values of u¯(x) defined in (1c) of Sec. 2. For the remainder
of the manuscript we take the step size ∆t = 0.02 with N = 60 equal time intervals and the
leak coefficient is set to γ = 0.002. For the implementation of the problem (10), we use the
open source finite element C++ library FeMUS [32].
3.2 Incorporating the diffusion tensor
Diffusion patterns of water molecules in biological tissue can be visualized by means of diffu-
sion tensor magnetic resonance imaging (DTI). The diffusivity in the medium is quantified
at each image voxel (a volumetric pixel) with a diffusion tensor that relates diffusive flux to
a concentration gradient in each Cartesian direction. The three diagonal elements Dxx, Dyy,
and Dzz represent diffusion coefficients measured along each of the principal x−, y−, and
z− axes. The six off-diagonal entries quantify the correlation of Brownian motion between
corresponding principal directions. A generic diffusion tensor can be written as
D =
Dxx Dxy DxzDyx Dyy Dyz
Dzx Dzy Dzz
 , (11)
where Dij has the unit of mm
2/sec.
The diffusivities from DTI are usually averaged out and illustrated by condensing the
tensor information into a scalar quantity or plotted as a color encoded texture map. The
former consists of scalar measurements to quantify the magnitude or the shape of the diffu-
sion. In terms of magnitude, mean diffusivity (MD), which is the mean of the eigenvalues of
the diffusion tensor, is one of the most common scalar measurements. On the other hand,
fractional anisotropy (FA), which is the normalized variance of the eigenvalues, is the most
commonly used anisotropy measure. In addition to various scalar measurements, one can also
consider the direction of the major eigenvector (the eigenvector associated with the largest
eigenvalue) and create a color map for the corresponding directions. The most commonly
used color scheme in terms of anatomical planes is as follows; blue is superior-inferior, red
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is left-right, and green is anterior-posterior [22]. For an extensive overview of the diffusion
tensor imaging, the reader may refer to [33].
To capture the anisotropies of the diffusion in our numerical simulations we use a dataset
that includes a diffusion tensor magnetic resonance image of a 35-year old male diagnosed
with glioblastoma multiform (GBM). The dataset can be found in the tutorial [34]. From the
diffusivity data, in Fig. 1, we derive and display the major eigenvector direction (indicated by
the colors prescribed in the preceding paragraph), fractional anisotropy, and mean diffusivity.
In the figure the GBM region can be observed around the right frontal lobe.
(c)(b)(a)
Figure 1: Axial view of the brain DTI with illustrations from 3DSlicer of (a) the major
eigenvalue direction, (b) fractional anisotropy, and (c) mean diffusivity. In all images the
tumor region can be seen around the right frontal lobe.
The coordinate dimensions of the sample volume is 256×256×51 with voxel size 1×1×2.6
mm. In the pre-processing of the DTI volume, we utilized the open source software 3DSlicer
[35], which allows advanced medical image analysis and processing. It provides a graphical
user interface with various modules as well as a Python console, which gives access to data
arrays of image models for further analysis.
The diffusion tensor is symmetric and positive definite (SPD) but in practice the positive
definiteness can be corrupted due to measurement noise. Thus we first re-sample the DTI
volume to correct the tensors that are not positive semi-definite. We are particularly inter-
ested in diffusion in the tumor tissue. Hence, we extract a region of 64× 64× 24 voxel-wise
enclosing the entire tumor region from the re-sampled volume and scale it into a cube Ω of
sides 5 centered at the origin,
Ω = {(x, y, z) : −2.5 ≤ x, y, z ≤ 2.5}. (12)
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We take Ω as the computational domain of the problem described in (1). After the re-scaling,
the tumor region fits completely inside the rectangular subdomain of Ω,
T = {(x, y, z) : −0.6 ≤ x ≤ 1.7,−1.5 ≤ y ≤ 1.5,−1.1 ≤ z ≤ 2.2} ⊂ Ω. (13)
It is convenient to rescale the tensor D over the region T defined in (13). Let
Di =
Dxx Dxy DxzDyx Dyy Dyz
Dzx Dzy Dzz
 (14)
be the diffusion tensor defined for the hexagonal element Ki in (5). Note that we define
D element-wise so it is essentially piece-wise discontinuous across the problem domain. Let
Dai = (Dxx + Dyy + Dzz)/3 be the element-wise apparent diffusion coefficient (ADC). We
will use Algorithm 1 to scale the diffusion tensors in Ω and also identify the tumor elements
in T.
Algorithm 1
N = number of elements
D = diffusion tensor
T = region enclosing the tumor bulk
AvgTr = 0, Counter = 0
for i = 1 : N do
if Ki ∈ T then
TrE = Dia
if TrE > 0.002 then
AvgTr = AvgTr + TrE
Counter = Counter + 1
end if
end if
end for
Scale = AvgTr/Counter
for i = 1 : N do
Di = Di/Scale
end for
We set a tumor boundary threshold value of 0.002 by visual inspection. If our element-
wise ADC Dai > 0.002 in the region T for the raw data, we label it as cancerous element.
With the algorithm above, the mean of ADCs across the assumed tumor elements is scaled
to unity.
A major prediction made in this investigation is the fraction of the tumor volume killed
against preassigned thresholds, uT (24), uT (48) and uT (72), from Sec. 2.1. This task essen-
tially requires the elementwise identification of the tumor cells in Ω. The only quantitative
information about the sample data are the diffusion tensors at each voxel provided by DTI.
No method is known to precisely differentiate the tumor and healthy cells by means of diffu-
sion tensor information. However, we employ the fact that water diffuses significantly faster
in GBM tissue than the surrounding healthy tissue [36].
We first assume that there is no tumor cell outside the region T. So, after the re-scaling
of the diffusion tensor with Algorithm 1, we will mark any element Ki in T as cancerous
if Dai > 0.6. This is the value where we observe a relatively sharp transition between the
8
normal and cancerous regions. To calculate the apoptosis fraction, first consider the unit
step function
H(s) =
{
1, s > 0,
0, s ≤ 0; (15)
and the sub-region TC ⊂ T defined as
TC = {x ∈ T : Dai (x) > 0.6} (16)
We compute the fraction of cells, i, that were once exposed to a concentration higher than
uT at the simulation time t = tn as follows,
i(τ, tn) =
∫
TC
H(maxt∈[0,tn] [u(x, t)− uT (τ)])dV∫
TC
dV
(17)
where τ = 24, 48 or 72 hours. Then to get the apoptosis fraction, ℵ, we prescribe tn = T in
(17),
ℵ(τ) = i(τ, T ). (18)
Note that the resulting fractions above are relative to the sub-region TC since we assume all
tumor cells lie in T.
Different cross sections of the computational domain Ω indicating the element-wise ADCs
can be seen in Fig. 2. We construct Ω to be consistent with the anatomical coordinate system
described in [37]. Positive directions of the x, y, and z axes are chosen to be anterior, left,
and superior, respectively. By this way, xy, xz, and xz coordinate planes correspond to
transverse, frontal, and sagittal planes, respectively. In Fig. 2, for example, the horizontal
plane with respect to the monitor corresponds to the transverse plane.
DTI is a non-invasive technique based on the measurement of the diffusion of water
molecules. Therefore, the diffusion tensor D may be quantitatively different across the tissue
of interest when another substance, such as a therapeutic agent, is used. Seemingly, there
is no experimental study proposing a numerical relationship between the diffusion tensor
of water and other fluids in brain tissue. Therefore, we will assume that although water
and corresponding drug molecules have different fluidic properties, they display qualitatively
similar behavior in the same medium. With this assumption, we will treat the diffusion
tensors that we extracted from the dataset, described above, as the diffusion tensors of the
agent used in the simulated treatment. For information on treatments of this type, the
reader can refer to [30, 31].
4 Results and predictions
In this section we present the in vivo direct injection treatment simulations resulting from
the numerical solutions of our model (1). Based on the location of T, we set the initial
condition (15) (illustrated in Fig. 3) as follows
u(x; t = 0) =
U0
Vb
{
exp
(
1− 1
1−r2
)
for r < 1,
0 for r ≥ 1; (19)
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Figure 2: Computational domain with three representative slices centered at xc = (0.5, 0, 0).
The heat map indicates the magnitude of the apparent diffusion coefficient (ADC) after the
scaling of the raw diffusion tensor data with Algorithm 1.
where Vb = 1.1990 and r =
√
(x− 0.5)2 + y2 + z2. By Algorithm 1, we scale the patient’s
water diffusivity tensor to D/0.00271734, which effectively reduces the temporal time step for
computation, and afterwards set the leak coefficient to be γ = 0.002 m/s, which mimics the
rate of diffusion for the scaled tensor. Further, a very high initial concentration of U0 = 1.5
µM is taken for illustrative purposes.
In Sec 2.1, we assumed that if the concentration at the element Ki is above a certain
threshold, uT (τ), at any simulation time, t, then Ki will die out after the corresponding
exposure times, τ . With this assumption, we can create a heat map indicating the regions
which is predicted to die after the related exposure times, τ = 24, 48, and 72 hours. It should
be noted that although the precise tumor region is TC , we will display the apoptotic region
within T for illustration purposes. Also note that the drugs eventually leak out beyond
the region TC , and contribute to toxicity. Since the response of the healthy cells to the
drug is a highly complex phenomenon, in the figures we will assume that any tissue element
experiencing concentration above the thresholds in Sec. 2.1 will be killed irrespective of the
location.
In Fig. 4, we present the apoptotic region induced by the initial bump function within
the tumor region T (Fig. 4a) and the entire computational domain Ω (Fig. Fig. 4b); that
is, the region of cells expected to die within an exposure time τ simply due to the initial
condition before any diffusive spreading has occurred. In the figure, the outermost red region
represents the location of the cells where the drug concentration is below any threshold value.
The innermost dark blue region shows the locations where the concentration is above the
threshold value uT (24), and the heat map illustrates regions where the concentration of the
bump function is above the respective threshold values.
As the drug diffuses across the computational domain, Ω, more cells are exposed to
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Figure 3: Initial concentration profile u(x; t = 0) centered at the location xc = (0.5, 0, 0)
with an initial injection molarity of U0 = 1.5 µM.
(b)(a)
Figure 4: Apoptotic region induced by the initial bump function centered at xc = (0.5, 0, 0),
with a very high drug concentration of U0 = 1.5 µM for illustration purposes, within (a) the
tumor region T and (b) the computational domain Ω. The inner most blue region shows
the locations where the tumor cells will die out within 24 hours. The outermost orange cells
are predicted to die out within 72 hours of exposure. Finally, the deep red cells towards the
outside of the regions do not die after up to 72 hours of exposure.
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the drug over the course of the simulation. Figure 5 shows the planar projections of the
concentration profiles as a heat map at increasing simulation times. Red represents a higher
concentration of drugs and deep blue represents a concentration of zero. To improve the
visibility of simulations, we scale the data to visible data range. The inhomogeneous -
anisotropic nature of the diffusion can be clearly observed from the concentration profiles in
Fig. 5.
(a) (b)
(c) (d)
Figure 5: Concentration profiles for an initial injection of U0 = 1.5 µM centered at xc =
(0.5, 0, 0) at t = 0.2, 0.5, 0.8, 1, [(a) - (d)] respectively. The heat map is scaled to the visible
range for each figure; i.e., the intensities are with respect to the concentration distribution in
each figure independently of the other figures. Each figure is displayed with the intersection
of three representative slices and two separate views of the frontal, yz-plane, and transverse
xy-plane. The inhomogeneous - anisotropic nature of the diffusion can be observed in the
planar slices accompanying the 3-D figures.
Now, we can compute the concentration levels at particular simulations times and com-
pare them to the threshold values. For a particular simulation time, tn, the volume fraction
of the tumor where the concentration is above the threshold, uT (τ), for the first time is
calculated and summed with that of all previous times ti where i < n, using (17). When
this is done for the final time, tn = T , which is chosen to be large enough that all of the
drug mixture leaks away after this time, then we have our apoptosis fraction, ℵ(τ) in (18).
We report the exact fractions, i(τ, tn), from (17) in Table 1. Note that the fourth column
is the final values that indicate the percentage of the tumor cells killed, ℵ(τ).
The effects of the inhomogeneous - anisotropic diffusion on apoptosis can be observed
in Fig. 6. For example, the drug efficacy is significantly higher on the transverse plane
compared to the sagital and frontal planes. This can be seen in Fig. 6h where the apoptotic
region covers almost the entire transverse plane, while nontrivial portions of the frontal plane
remains unscathed. Moreover, even though relatively high apoptosis fractions are achieved
12
(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 6: Cells with a drug concentration higher than the given threshold, i(τ, tn), at
simulation times tn = 0.2, 0.5, 0.8, 1 after an initial injection of U0 = 1.5 µM centered at
xc = (0.5, 0, 0). The column on the left, (a), (c), (e), (g), shows the entire computational
domain, Ω, and the column on the right, (b), (d), (f), (h), shows the tumor region, T.
Each figure is displayed with the intersection of three representative slices and two separate
views of the frontal, yz-plane, and transverse xy-plane. It is observed that the number of
cells exposed to a sufficient amount of drugs is higher on transverse, compared to the sagital,
xz-plane, and the frontal plane. The inner most blue region shows the locations where
u(x, t) > uT (τ = 24hours) for any t = tn. The outermost orange cells correspond to τ = 72
hours. Finally, the deep red cells towards the outside of the regions has concentrations
u(x, t) < uT (τ) for all t and τ .
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Table 1: Convergence of apoptosis fraction approximation for U0 = 1.5 µM
tn = 0.2 tn = 0.5 tn = 0.8 tn = 1 tn = 1.2
i(24, tn) 0.498408 0.528229 0.528229 0.528229 0.528229
i(48, tn) 0.698709 0.814072 0.864979 0.873871 0.877210
i(72, tn) 0.750721 0.878613 0.909647 0.915700 0.921299
in the tumor region, T, it is observed in Fig. 7 that significant amounts of the drug leak out
of T. So our results indicate that considerable portions of the healthy cells are subject to
toxicity. We can visually inspect the leakage of the drug by superimposing the representative
slices of the computational domain Ω and the sub-region T (Fig. 7).
(a) (b)
(c) (d)
Figure 7: A visual demonstration of toxicity. The effect of the threshold is extended beyond
the tumor region, T, (the dark blue rectangular mesh), and the heat map is calculated in
the yz, xz, and xy-planes from (17) at simulation times tn = 0, 0.2, 0.5, 1, [(a) - (d)]
respectively. It is observed that most of the drug mixture eventually diffuses outside of the
tumor region. Thus, significant portions of healthy cells may potentially be subjected to
toxicity. The inner most blue region shows the locations where u(x, t) > uT (τ = 24hours)
for any t = tn. The outermost orange cells correspond to τ = 72 hours. Finally, the deep
red cells towards the outside of the regions has concentrations u(x, t) < uT (τ) for all t and
τ .
It is observed in Table 1 that the current configuration of the problem leads to partial
ablation in the tumor region since 92 % of the region dies after 72 hours. In fact, as shown in
the dose-response curves in Fig. 8, the apoptosis fraction seemingly asymptotes as we increase
the amount of initial injection because the interaction of the drug with several obstacles, local
inhomogeneities, and leakage, do not allow sufficient concentrations to diffuse to every part of
14
the tumor region. Thus, we can conclude that our mechanistic model is capable of reflecting
the diffusion patterns mostly governed by location-wise structural differences.
Considering the internal injection scenario, several ways can be proposed to improve the
efficacy of the drug without changing its fluidic properties. An obvious way may be to use a
higher initial concentration, U0. In fact, we can create dose-response curves for a broader view
of the effects of various initial concentrations U0 on the final apoptosis fractions. Figure 8
demonstrates the final percentages of the tumor that is killed for 31 different initial injections
varying from U0 = 0.01 µM to U0 = 5 µM. Dose-response curves reveal that even though the
initial injection is excessively elevated, it is not possible to reach a complete tumor ablation.
Indeed it is observed that apoptosis fractions barely improve after approximately U0 = 2
µM for τ = 48 and 72 hours exposure times. We reported in Fig. 7 that even U0 = 1.5
µM causes the presence of significant concentrations of drugs outside of the tumor region T.
Thus we can conclude that the use of initial drug concentrations outside of a certain range
is prohibitive and can severely contribute to toxicity.
Figure 8: Dose-response curves (24, 48, and 72 hours from bottom to top) produced from
31 different initial injections varying from over the interval [0.01, 5]. It can be seen that the
apoptosis fraction starts to asymptote beyond U0 = 2 for 48 and 72 hours exposure options.
Another important parameter effecting the apotosis fraction is the location of injection.
Our initial choice as the center of the bump function is (0.5, 0, 0), which we pick by visual
inspection to be near the center of the tumor. We found that changing the injection lo-
cation greatly effects the diffusion pattern, and hence the final apoptosis fraction. In this
sense, an important prediction in this investigation is that a seemingly poor location in T
in terms of the distance from the center of the tumor bulk can yield higher apoptosis frac-
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tions than some locations that are close to the tumor center. To illustrate this phenomenon,
in Fig. 9, we choose four different injections points P1(0.5,−0.3,−0.5), P2(−0.3, 0,−0.6),
P3(−0.3,−0.3,−0.6), and P4(0, 1, 0), and create dose response curves for each location. Our
results demonstrate that finding the optimal injection location to maximize apoptosis frac-
tions is quite an unpredictable process and cannot be achieved with a basic visual inspection.
For example, we pick P4 to be the “poor” location considering its position relative to the
center of the tumor, and expected to get lower apoptosis fractions compared to the other
locations, but Fig. 9 shows a different outcome. Although P1, P2, and P3 yield relatively
similar patterns, P4 produces a better results for 48 and 72 exposure times after U0 = 0.8.
However, efficacy is remarkably low for P1 comparing to others if one opts to measure the
apoptosis after 24 hours. We should also note that similar to the initial findings, none of
these configurations lead to full ablation in the tumor region.
(a) (b) (c)
Figure 9: Dose-response curves with 4 different injection points: P1(0.5,−0.3,−0.5),
P2(−0.3, 0,−0.6), P3(−0.3,−0.3,−0.6), and P4(0, 1, 0). (a) 24 hour dose-response curves.
(b) 48 hour dose-response curves. (c) 72 hour dose-response curves. Although P4 is picked
as an intuitively “poor” location in terms of distance to the center of the tumor bulk, it
yields better efficacy for 48 and 72 hour exposure times after U0 = 1 µM and U0 = 0.7 µM,
respectively.
We can further investigate this idea in a slightly different context. Let us manually choose
20 different injection points around the tumor region and calculate the apoptosis fractions by
fixing the initial injection to U0 = 1.5 µM. We then label corresponding locations with these
fractions and display them inside the tumor region T in Fig. 10. In the figure, blue points
represent lower efficacy (69%) and red points represent higher efficacy (90%) for an exposure
of 72 hours. It is observed that the injection location has a significant influence on the
efficacy of the drug. For example, in Fig. 10, P4(0, 1, 0) (the right most red point) from Fig.
9 is represented and had a much higher efficacy than several points taken around the center.
In a realistic treatment case, one can increase the number of points used in the simulations
to obtain broader information about the optimal injection sites. However, if the same figure
is created with a sufficient number of injection points around (and even outside) the tumor
region, we can create a more fine-grained apoptosis heat map. In this way, we can obtain a
volumetric partition of the tissue of interest with respect to mean apoptosis fractions. Such
a work-flow can allow practitioners to determine the optimal infusion locations. Once the
corresponding partition is identified, we can utilize the simulation to find an ideal injection
amount which can strike a balance between toxicity and efficacy.
In 3D simulations, computation time is undoubtedly of great importance and essentially
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(a)
(b)
Figure 10: Location based apoptosis fractions with U0 = 1.5 µM based on 20 injection points.
The numbers attached to the points are the predicted apoptosis fractions at these locations.
(b) is a magnified version of (a).
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determines if the proposed model is feasible in practical applications. In finite element
models, the type and number of elements in the computational domain is the primary fac-
tor effecting the computation time. In this paper, we constructed the domain with 98403
bi-quadratic hexagonal elements. Our computing environment is 9th Generation Intel(R)
Core(TM) i7-9750H (12MB Cache, up to 4.5GHz, 6 cores) with 32GB DDR4-2666MHz
RAM. We run the simulations with an MPI-based parallel environment on four cores and
observed that computation time is approximately 15 minutes for one simulation with an
initial injection of U0 = 1.5 µM and an output of apoptosis fractions for a given threshold,
uT (τ), the results of which are reported in Table 1 and 5.2 hours to create the dose-response
curve using 31 initial injection values in Fig. 8. We should carefully note that the number
of elements in this framework should be completely determined by the dimension of the
diffusion tensor volume extracted from the original data. Thus, to be able to describe the
corresponding quantities in finer detail, diffusion tensor images with higher resolutions are
needed, but in this case we need a more powerful environment to obtain the results in a
reasonable computing time.
In future studies, a more realistic computational domain may be created. For simplicity,
we worked with a cubic domain in this study. However, it may possible to locate and cut
out the tumor region more accurately and create a volumetric mesh based on this segmented
region. A rough description of the tumor region extracted from the original data can be
seen in red in Fig. 11. We display the tumor along with a discretized representation of the
brain. We can then feed this mesh structure into the existing model. This approach has the
potential to generate a more realistic model, but it can be quite challenging. For example, we
would need to properly address how to interpolate the diffusion tensors across the boundary
of this new domain if boundary conditions are to be imposed only on the surface of the
tumor volume.
5 Conclusion and future work
Brain tissue poses a unique transport challenge due to the highly inhomogeneous - anisotropic
nature of the medium. Since drug exposure directly impacts cell death, the geometry and
topography of the tumor will have a significant effect on efficacy. Further, the tumor will also
grow in an inhomogeneous - anisotropic manner [18, 19, 20, 21], and hence its structure can be
quite unpredictable. Diffusion Tensor Magnetic Resonance Imaging (DTI) provides structure
level information on an individual basis [22]. While there have been articles on employing
DTI to study drug transport in the brain [5], thus far none have simulated the efficacy of a
drug as a consequence of drug transport. With a drug transport - tumor population coupled
model, there is potential in producing computer aided treatment strategies.
In this paper, we derived an inhomogeneous - anisotropic drug diffusion model of molarity
u(x, t), with the drug mixture injected into a porous tumor region in Sec. 2. Then in
Sec. 2.1, we developed the binary population model, where natural tumor cell death is
equivalent to the rate of tumor population growth and cell death due to the drug occurs
when u(x, t) > uT (τ) for a concentration threshold uT and exposure time τ , similar to that
of [17]. The model is solved numerically, in Sec. 3 through our finite element method.
Since information on the diffusion tensor is imperative to the numerical solution, the model
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Figure 11: Approximate tumor region segmented from the original DTI volume. The solid
tumor can be seen in red along with a discretized representation of the brain
employs DTI data (Sec. 3.2) of a 35-year old male diagnosed with glioblastoma multiform
(GBM). This DTI data was pre-processed with an open source medical image processing
software 3DSlicer [35] and fed into our finite element framework. In Sec. 4 we present the
results from the simulation in a form that can be used by oncologists and doctors, and make
predictions that may be easily overlooked in practice. We investigated apoptosis fractions
in the tumor region through the binary population model in Sec. 2.1 This allowed us to plot
dose-response curves and test various injection locations. Importantly, the various locations
show that the intuitive choice may not always be the best. This opens the door to develop
tools to aid oncologists and doctors in deciding on an optimal treatment strategy.
The response of cancer cells to a therapeutic agent is undoubtedly a highly complex
phenomenon. However, some aspects of it can be addressed with the help of a mathematical
model. In this sense, our aim in this study was to build a partial differential equation
framework based on patient-specific data that can be used to predict the efficacy of drug
diffusion in the brain tissue occupied by tumor cells. Moreover, this framework may be
used to create diffusion models which take into account more complex considerations. For
example, a problem encountered in some cancer therapies is drug resistance, which can
be defined as the ability of cancer cells to survive and grow despite various anti-cancer
treatments [38]. Further, oxygen concentration also has an effect on drug efficacy [39, 40, 41,
42]. In this paper, we assumed that the tumor cells exposed to a drug concentration above
certain threshold values will be ablated after the corresponding exposure times. However,
if reliable empirical knowledge is present about drug resistance and oxygen concentration, a
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time dependent or location-based threshold model may be integrated into this framework.
In this regard, using finite element method in the model provides a great flexibility since it
allows us to attach scalar quantities in the desired locations.
In addition, while the binary population model has computational advances due to its
simplicity, a more accurate model would be a stochastic dynamical system that is depen-
dent on the concentration threshold. One concern may be the complexity of coupling, but
fortunately transport happens on a much faster timescale than apoptosis. We would solve
the partial differential equations for the transport, and then tackle the population dynamics
to produce the apoptosis fractions. However, as with any model, adding more complexity is
counterproductive unless it is accompanied by reliable data. This gives us a singular oppor-
tunity to develop both biological and physical experiments to accurately estimate parameters
and test the models.
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